docihi - sorry to hear that you are departing your CRIS investment. I do want to thank you for your helpful input on this board over the past several years. Please do drop back to tell us where else you are roaming in biotech.
derek - today an ASCO abstract came out with a 'no statistical effect' for Erivedge in esophageal cancer. A disappointment, and with all of the recent directional shifts, I'm sure more than a few hands sold out. I look at 2013 and see Euro approval, 907 progress, and at the end ... Operable BCC as potential high points - but right now, the sentiment is low.